1. Introduction {#sec1-viruses-12-00630}
===============

Coronaviruses (CoVs) are an enveloped, single positive-strand RNA species of viruses belonging to the *Coronaviridae* family, which infect birds and mammals. In animals, CoVs cause respiratory, enteric, cardio-vascular, and neurological disorders \[[@B1-viruses-12-00630]\]. In humans, these viruses result in respiratory and gastro-intestinal symptoms, ranging from cold symptoms to severe diseases \[[@B2-viruses-12-00630],[@B3-viruses-12-00630]\].

CoVs recognized to infect humans belong to the genera *Alphacoronavirus* and *Betacoronavirus* \[[@B4-viruses-12-00630]\]. Seven CoV species are known to cause human infection, of which four HCoVs (namely HCoV 229E, NL63, OC43, and HKU1) are known as non-severe acute respiratory syndrome (SARS)-like CoVs. HCoV-229E and HCoV-NL63 belong to the genus *Alphacoronavirus*. The genus *Betacoronavirus* includes HCoV-HKU1, HCoV-OC43, SARS-CoV-1 \[[@B5-viruses-12-00630]\], the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) \[[@B6-viruses-12-00630]\], and the SARS-CoV-2, which is currently associated with a global outbreak \[[@B7-viruses-12-00630]\].

The four non-SARS/MERS species circulate widely in humans and infect individuals of all ages \[[@B8-viruses-12-00630],[@B9-viruses-12-00630]\]. HCoV-229E and HCoV-OC43 were identified in 1967 and were primarily associated with mild upper respiratory tract infections \[[@B10-viruses-12-00630],[@B11-viruses-12-00630]\]. HCoV-NL63 was identified in 2004 from a 7-month-old child suffering from bronchiolitis and conjunctivitis \[[@B12-viruses-12-00630]\] and HCoV-HKU1 was discovered in 2005 in Hong Kong and isolated from patients with pneumonia \[[@B13-viruses-12-00630]\]. In general, the four common circulating HCoVs mostly infect humans during the winter season (December--April) \[[@B14-viruses-12-00630]\], whereas circulation of HCoV-HKU1 has been observed during the spring--summer period \[[@B9-viruses-12-00630]\].

The World Health Organization has highlighted the need to improve epidemiological surveillance and knowledge of the health burden imposed by non-influenza respiratory viruses \[[@B15-viruses-12-00630]\]. HCoVs are generally associated with mild upper respiratory tract infections \[[@B16-viruses-12-00630]\], but severe infections with HCoV-229E, HCoV-NL63, and HCoV-OC43 have been reported \[[@B17-viruses-12-00630],[@B18-viruses-12-00630],[@B19-viruses-12-00630]\].

In the context of the spread of SARS-CoV-2 in the community, a better understanding of the seasonality and clinical features of patients with confirmed HCoVs could be useful for mathematical modelling and clinical diagnosis. There is currently a debate about HCoV seasonality and pathogenicity, as epidemiological data are scarce and mostly from hospitalized populations. Here, we document the epidemiological and clinical features of HCoV patients with acute respiratory infection (ARI) observed in general practice. We also describe HCoV seasonality over six influenza surveillance seasons (2014/2015 to 2019/2020) in Corsica, France.

2. Materials and Methods {#sec2-viruses-12-00630}
========================

2.1. Clinical Samples {#sec2dot1-viruses-12-00630}
---------------------

Nasopharyngeal samples were collected: i) as part of the community influenza surveillance conducted in collaboration with the French *Sentinelles* Network from patients seen in general practice, consulting for influenza-like illness (ILI) or ARI (for patients aged \>65 years old) during six influenza seasons (week 40 to 15 of each season) from 2014 to 2020 in Corsica, France; and ii) from ARI patients enrolled throughout mainland France by general practitioners (GPs) of the French *Sentinelles* Network, during an epidemiological study of the risk factors for seasonal influenza (IRIIS study; 2014--2016 influenza seasons (week 40 to 15)) \[[@B20-viruses-12-00630]\]. Notably, to ensure that the selection of ILI/ARI patients remained random, each GP was required to include, each week, the first two patients unrelated to one another, consulting within \<48 h since symptom onset and consenting to provide a nasopharyngeal specimen. Each patient could be included only once a year ([Table 1](#viruses-12-00630-t001){ref-type="table"} and [Figure 1](#viruses-12-00630-f001){ref-type="fig"}). The surveillance uses a specific definition of ILI for patient recruitment: sudden onset of fever \>39 °C with myalgia and respiratory signs, diagnosed by the physician. The case definition of ARI was "any person with a sudden onset of symptoms and at least one of the following four systemic symptoms: fever or feverishness, malaise, headache, myalgia, and at least one of the following three respiratory symptoms: cough, sore throat, or shortness of breath."

2.2. Viral Diagnostic Testing {#sec2dot2-viruses-12-00630}
-----------------------------

Viral genome was extracted from 200 μL of patient samples using the QIAamp MinElute Virus Spin Kit (Qiagen, France). Routine molecular testing by real-time RT-PCR (rtRT-PCR) using an FTD Respiratory pathogens 21 Kit (Fast Track Diagnostics, Luxembourg) was employed from 2017/2018 onwards to detect: influenza viruses (subtypes A and B: flu A and flu B), human rhinovirus (HRV), human coronaviruses NL63 (HCoV-NL63), 229E (HCoV-229E), OC43 (HCoV-OC43), and HKU1 (HCoV-HKU1), respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human adenovirus (HAdV), human parainfluenza virus (HPIV), and human bocavirus (HBoV). Samples collected in 2014/2015 and 2016/2017 were analysed by ARGENE^®^ Respiratory Range (Marcy l'Etoile, France). This rRT-PCR did not provide details for HCoVs and HAdV, HBoV, and HPIV were not analysed. Thus, samples still available were retrospectively analysed for CoV-229E, CoV-OC43, and CoV-NL63 by FTD.

All nasopharyngeal samples collected by the French *Sentinelles* Network during the 2019/2020 season were analysed for SARS-CoV-2. RdRp-IP1 and RdRp quantitative rtRT-PCR was used for detection of SARS-CoV-2. The RdRp rtRT-PCR corresponds to the Charité protocol \[[@B21-viruses-12-00630]\]. When a sample was positive for RdRp-IP1, quantification of the number of RNA copies was performed according to a scale ranging from 10^3^ to 10^7^ copies per μL \[[@B22-viruses-12-00630]\]. All analyses were conducted by the Laboratory of Virology, University of Corsica.

2.3. Seasonality of HCoVs in ILI/ARI Patients in General Practice {#sec2dot3-viruses-12-00630}
-----------------------------------------------------------------

The HCoV seasonality in Corsica from 2014/2015 to 2019/2020 was studied using samples collected by GPs of the Corsican *Sentinelles* Network, as constant and homogeneous monitoring of this population of ILI/ARI patients has been conducted throughout six influenza seasons ([Table 1](#viruses-12-00630-t001){ref-type="table"} and [Figure 1](#viruses-12-00630-f001){ref-type="fig"}).

To study the weekly number of HCoVs detected among ILI/ARI patients seen in general practice during the six influenza seasons, we gathered all samples collected by GPs for influenza surveillance and for the IRIIS study ([Table 1](#viruses-12-00630-t001){ref-type="table"} and [Figure 1](#viruses-12-00630-f001){ref-type="fig"}).

2.4. Ethical Considerations {#sec2dot4-viruses-12-00630}
---------------------------

The samples were obtained as part of influenza surveillance. The protocol was conducted in agreement with the Helsinki Declaration. We obtained authorization from the French Data Protection Agency (CNIL\#471393). The IRIIS study was approved by the Ethics Committee (CPP SUD MEDITERRANEE V, 01/09/2014; ref. number 14.078).

2.5. Statistical Analysis {#sec2dot5-viruses-12-00630}
-------------------------

Differences according to viral infection and epidemiological data (sex, age, clinical symptoms, and risk factors) were analysed and tested using Fisher's exact test or Chi-square test. Results were considered statistically significant when the *p* value was lower than 0.05. All statistical analyses were performed using R software version 3.6.1 (R Foundation, Vienna, Austria).

3. Results {#sec3-viruses-12-00630}
==========

3.1. HCoV Prevalence over Six Influenza Seasons among Patients with ILI/ARI Seen in General Practice in Corsica {#sec3dot1-viruses-12-00630}
---------------------------------------------------------------------------------------------------------------

During the six-year study, among the 811 ILI/ARI patients enrolled by the Corsican *Sentinelles* Network, 63.3% (*n* = 513) were positive for at least one of the respiratory viruses analysed ([Table 2](#viruses-12-00630-t002){ref-type="table"}). HCoVs were the third most frequently detected viruses (7.0%; *n* = 57) after influenza viruses subtypes A (32.4%; *n* = 263) and B (12.9%; *n* = 105) ([Table 2](#viruses-12-00630-t002){ref-type="table"}). The number of HCoV infections ranged from 4.5% in 2014/2015 (6 of 133) to 10.0% in 2016/2017 (14 of 140) ([Table 2](#viruses-12-00630-t002){ref-type="table"}). The contribution of HCoVs to the total number of viral detections (*n* = 547) ([Figure 2](#viruses-12-00630-f002){ref-type="fig"}) in the 811 ILI/ARI patients during each influenza season (week 40 to week 15) ranged from 6.9% (8 of 116) in 2017/2018 to 14.7% (11 of 75) in 2019/2020.

3.2. Seasonality of HCoVs {#sec3dot2-viruses-12-00630}
-------------------------

The seasonal distribution per week of HCoV, influenza viruses (A and B), RSV, and HRV was studied in 1389 ILI/ARI patients ([Table 1](#viruses-12-00630-t001){ref-type="table"} and [Figure 3](#viruses-12-00630-f003){ref-type="fig"}). Among the 1389 patients, 59.6% (*n* = 828) were positive for at least one respiratory virus, of which 39.6% (*n* = 328) were positive for influenza A virus, 25.6% (*n* = 212) for influenza B virus, and 12.6% (*n* = 105) for HCoVs. HCoVs were detected during the entire winter season (weeks 48--14), with the highest number of HCoVs detected in week 6 ([Figure 3](#viruses-12-00630-f003){ref-type="fig"}). Notably, week 6 had a decrease in influenza A virus detection ([Figure 3](#viruses-12-00630-f003){ref-type="fig"}). Since the number of HCoVs detected by species per season was low, the seasonality of HCoVs was established from all viruses detected per week over the six influenza seasons. The HCoV peak trend detection among week 4 to 7 was clearly observed during three influenza seasons (2014/2015; 2015/2016; 2019/2020).

Among the 105 HCoV cases, 82.8% (*n* = 87) were typed. Of these 32.2% (*n* = 28) of cases were infected with HCoV-OC43, 24.1% (*n* = 21) with HCoV-NL63, 22.9% (*n* = 20) with HCoV-HKU1, and 20.6% (*n* = 18) with HCoV-229E ([Table 1](#viruses-12-00630-t001){ref-type="table"}). The weekly number of HCoV types detected among the 1389 ILI/ARI patients is illustrated in [Figure 3](#viruses-12-00630-f003){ref-type="fig"}. A degree of synchrony was observed during all winter seasons and in the timing of the peak (week 6) for HCoV-HKU1, NL63, and 229E, whereas HCoV-OC43 infections occurred earlier with a peak in weeks 50--52 ([Figure 4](#viruses-12-00630-f004){ref-type="fig"}).

3.3. Co-Infection in HCoV-Positive Patients {#sec3dot3-viruses-12-00630}
-------------------------------------------

Among the 1389 ILI/ARI patients, 105 (7.5%) were positive for at least one HCoV. Among them, 82 (78.1%) were infected with one HCoV, while 23 (21.9%) were infected with at least two different respiratory viruses (including two co-infections with three viruses) ([Table 3](#viruses-12-00630-t003){ref-type="table"}). Of these, the most frequently observed co-pathogens were influenza viruses (flu A: *n* = 9/23; 39.1%, and flu B: *n* = 8/23; 34.8%) ([Table 3](#viruses-12-00630-t003){ref-type="table"}). Two co-infection combinations were detected: HCoV-229E/NL63 and HCoV-HKU1/OC43.

3.4. Age Distribution of HCoV-Positive Patients {#sec3dot4-viruses-12-00630}
-----------------------------------------------

The demographic data and clinical characteristics of the 105 confirmed HCoV-positive patients are summarized in [Table 4](#viruses-12-00630-t004){ref-type="table"}. The age of patients infected with HCoV varied from 1 month to 90 years with mean and median ages of 34 years. The male to female ratio of HCoV-infected patients was 1.06 (54/51). HCoV infections were observed in all age groups ([Table 4](#viruses-12-00630-t004){ref-type="table"} and [Figure 5](#viruses-12-00630-f005){ref-type="fig"}). However, the detection rates in these different age groups varied significantly (*p* = 0.00005) with the age group of 0--14 years accounting for 28.6% (*n* = 30) of HCoV-positive patients. In the remaining groups, detection rates were observed of 13.3% (*n* = 14) in the 15--29 age group, 20% (*n* = 21) in the 30--44 age group, 23.8% (*n* = 25) in the 45--59 age group, 9.5% (*n* = 10) in the 60--74 age group, and 4.8% (*n* = 5) in the group aged ≥75 years old.

HCoV-OC43 and HCoV-HKU1 were detected in patients of all ages ([Table 5](#viruses-12-00630-t005){ref-type="table"} and [Figure 5](#viruses-12-00630-f005){ref-type="fig"}). The oldest patients (≥75 years old) were infected by HCoV-OC43 and HCoV-HKU1 only ([Figure 5](#viruses-12-00630-f005){ref-type="fig"}A), and HCoV-HKU1 was the most prevalent among patients aged ≥60 years old ([Figure 5](#viruses-12-00630-f005){ref-type="fig"}B), but a significant difference in the age-group distribution of HCoV species was not observed ([Table 5](#viruses-12-00630-t005){ref-type="table"}).

3.5. Clinical Characteristics of ARI/ILI Patients and Comparison of Patients according to Their Viral Infection {#sec3dot5-viruses-12-00630}
---------------------------------------------------------------------------------------------------------------

The epidemiological and clinical features of patients were compared according to their viral infection: influenza A cases, influenza B cases, and HCoV cases (single or co-infection). Fever and malaise were less frequent in HCoV patients than in influenza patients, while sore throat, dyspnoea, rhinorrhoea, and conjunctivitis were more frequently associated with HCoV positivity ([Table 4](#viruses-12-00630-t004){ref-type="table"}). Sore throat and dyspnoea were more frequently detected in patients with HCoV single infection (75.3%, 55/82) than in patients with HCoV co-infection (42.9%, 9/23; *p* = 0.006) ([Table 4](#viruses-12-00630-t004){ref-type="table"}). Notably, oseltamivir was prescribed more frequently to influenza A patients ([Table 4](#viruses-12-00630-t004){ref-type="table"}).

Lastly, when comparing epidemiological and clinical features of patients according to the HCoV strain detected, there was a significant effect on the prevalence of sex (*p* = 0.002), with the HCoV-229E strain detected more frequently in male patients (88.9%) ([Table 5](#viruses-12-00630-t005){ref-type="table"}). A significant difference in the prevalence of malaise (*p* = 0.025) among HCoV strain patients was also identified, as this symptom was exclusively related to HCoV-HKU1 patients (15.8%, 3/20) ([Table 5](#viruses-12-00630-t005){ref-type="table"}).

3.6. Clinical Description of SARS-CoV-2-Positive Patients Seen in General Practice {#sec3dot6-viruses-12-00630}
----------------------------------------------------------------------------------

Among the 119 ARI patient samples collected during the 2019/2020 influenza season and tested retrospectively for SARS-CoV-2 from week 40 to week 15, four (3.3%) were positive for SARS-CoV-2. These four infections were detected during weeks 11 (*n* = 1), 14 (*n* = 2), and 15 (*n* = 1). Fever, cough, and headache were the most commonly declared symptoms, while anosmia was reported for one patient. The mean age of the four patients was 60.75 years and the sex ratio was 1:1 (two women and two men).

4. Discussion {#sec4-viruses-12-00630}
=============

Data from continuous surveillance are very important for identifying the pattern of HCoV epidemiology. This report is the first to describe patterns of circulation of the four common HCoV strains in French ILI/ARI patients seen in general practice over six influenza seasons. HCoV was the third most detected respiratory virus in ARI/ILI patients after the influenza A and B viruses. Similar to their susceptibility to other respiratory viruses, young children aged \<14 years old had the highest risk of HCoV infection. Sore throat, dyspnoea, and conjunctivitis were more frequently described among HCoV cases than among influenza cases.

Similar to other countries in the northern hemisphere, we reported a winter seasonal prevalence pattern for the four HCoV strains \[[@B23-viruses-12-00630]\], with the highest number of cases presenting in February \[[@B9-viruses-12-00630],[@B24-viruses-12-00630]\]. In our study, the peak in February was attributable to the 229E, NL63, and HKU1 strains, whereas the OC43 strain had peaks in December. Overall, among the HCoV-positive patients in this study, the OC43 strain was the most commonly detected virus, followed by the NL63, HKU1, and 229E strains, in agreement with previous studies \[[@B9-viruses-12-00630],[@B25-viruses-12-00630],[@B26-viruses-12-00630]\]. HCoV-OC43 is routinely associated with \~5% of acute respiratory infections and was the most commonly detected virus in HCoV patients \[[@B27-viruses-12-00630],[@B28-viruses-12-00630],[@B29-viruses-12-00630]\]. A seroconversion study in hospitalized children reported that HCoV-OC43 and HCoV-NL63 might induce cross-immunity, and therefore reduce the subsequent number of clinically identified HCoV-HKU1 and HCoV-229E infections \[[@B30-viruses-12-00630]\].

We confirmed that, similar to other respiratory pathogens, HCoVs were widespread in all age groups \[[@B31-viruses-12-00630]\]. A significant difference in the age distribution of HCoV patients was noted, with the youngest (0--14 years old) patients displaying a threefold higher level of infection than those aged 60--74 years old and a sevenfold higher infection level than patients aged ≥75 years old. Among HCoV patients aged \<60 years old, the most frequently detected viruses were HCoV-OC43 and HCoV-NL63, while among patients aged ≥60 years old, HCoV-HKU1 was the most frequently detected. This trend of HCoVs infection has already been reported in other studies \[[@B14-viruses-12-00630],[@B25-viruses-12-00630],[@B26-viruses-12-00630],[@B29-viruses-12-00630]\]. A recent surveillance study on the occurrence and hospitalization rates in children with respiratory infections over 9 years reported that HCoVs were involved in 9.1% of episodes \[[@B25-viruses-12-00630]\]. To date, in contrast to that observed for HCoVs, few SARS-CoV-2 have been observed in children. Official national statistics in Italy reported that 1% of total cases diagnosed country-wide were below 20 years \[[@B32-viruses-12-00630]\]. It could be possible that pre-existing cross-immunity provides protection and/or reduces the severity of COVID-19, thereby reducing the number of children who are tested/hospitalized \[[@B33-viruses-12-00630]\]. The fewer number of HCoV infections in older than younger patients may result from higher antibody levels or other immune mechanisms of protection \[[@B34-viruses-12-00630]\]. The lower number of HCoV infections in older than younger patients may result from higher antibody levels or other immune mechanisms of protection \[[@B34-viruses-12-00630]\]. It is well known that HCoVs co-circulate endemically with other common respiratory viruses and co-infections are frequently observed. In our study, six other common respiratory viruses were detected simultaneously and 21.9% of the HCoV-positive patients were co-infected by at least one of the other respiratory viruses. The occurrence of co-infection of HCoV, including other HCoVs, RSV, influenza A and B viruses, HAdV, and HMPV has been reported \[[@B29-viruses-12-00630],[@B35-viruses-12-00630]\]. Similar to other studies, we observed that influenza and RSV were the most common respiratory viruses co-infected with HCoV \[[@B27-viruses-12-00630],[@B36-viruses-12-00630]\]. We did not observe co-infection of SARS-CoV-2 and another respiratory virus among the four COVID-19 patients detected. A recent co-infection of SARS-CoV-2 and HCoV-HKU1 has been reported \[[@B37-viruses-12-00630]\].

In this study, we compared the demographic data and clinical characteristics of HCoV patients with those of influenza A and B patients, respectively ([Table 4](#viruses-12-00630-t004){ref-type="table"}). Sore throat, dyspnoea, rhinorrhoea, and conjunctivitis were more often observed in HCoV cases than in influenza cases. While dyspnoea was reported as not common in seasonal influenza viruses \[[@B38-viruses-12-00630]\], studies of hospitalized patients reported the role of HCoV in causing lower respiratory illness \[[@B13-viruses-12-00630],[@B26-viruses-12-00630]\]. Fever was more often observed in influenza cases, as reported \[[@B23-viruses-12-00630]\]. These observations may be of importance, especially when HCoVs and influenza virus co-circulate. The clinical impact of HCoVs in co-detection is not fully understood, with previous studies observing unchanged morbidity or increased illness severity \[[@B39-viruses-12-00630]\]. When we compared the clinical presentations of patients with a single HCoV infection with those with co-infection, sore throat and dyspnoea were more commonly reported in cases with a single infection.

A growing number of studies are currently describing the clinical features due to SARS-CoV-2 infection \[[@B40-viruses-12-00630],[@B41-viruses-12-00630],[@B42-viruses-12-00630],[@B43-viruses-12-00630],[@B44-viruses-12-00630]\]. Although most of the COVID-19 studies have been conducted on hospitalized patients some comparisons with data of the present study might be useful. Fever and cough were the most common symptoms reported for SARS-CoV-2 and HCoV patients \[[@B45-viruses-12-00630]\]. Compared to symptoms observed in HCoV patients included in the present study, SARS-CoV-2 patients seem to show less headache (6.3%--33.9% vs. 80.8%), rhinorrhea (4% vs. 87.7%) and myalgia (11.1--34.8% vs. 71.9%) \[[@B45-viruses-12-00630]\]. Sore throat, which was one of the most detected symptoms among HCoVs patients, was less common among COVID-19 patients \[[@B43-viruses-12-00630]\]. About half of COVID-19 patients had an underlying disease \[[@B45-viruses-12-00630]\], whereas in our study less than a quarter of the HCoV patients suffered from an underlying disease.

This study has some limitations. First, we used two ILI/ARI patient samples, which can introduce bias, even if the methodology of enrolment was very similar. Second, the number of HCoV patients included did not allow the identification of meaningful associations by subanalyses. Third, we studied HCoV circulation during influenza season and not on annual basis. As previously described, HCoVs co-circulate and showed marked winter seasonality, and are not detected in the summer period \[[@B14-viruses-12-00630]\]. Lastly, we did not identify the species of 20 HCoV cases because relevant samples were not available.

In conclusion, this study demonstrates that HCoV subtypes appear in ARI/ILI patients seen in general practice, with characteristic outbreak patterns primarily in winter. HCoVs were detected at a significantly higher rate in children aged \<14 years old than in older patients aged ≥60 years. Some clinical manifestations seem to differentiate HCoV patients from influenza patients. Further studies with representative samples should be conducted to provide additional insights into the epidemiology and clinical features of HCoVs.
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viruses-12-00630-t001_Table 1

###### 

Samples from 2014/2015 to 2019/2020 included in the study.

  Origin of Samples        Period (Week 40 to 15)   *N*    HCoVs          229E        OC43        NL63        HKU1        Not Typed
  ------------------------ ------------------------ ------ -------------- ----------- ----------- ----------- ----------- -----------
  Influenza Surveillance   2014/2015 to 2019/2020   811    57 (7.0)       12 (21.0)   20 (35.1)   11 (19.3)   11 (19.3)   3 (5.3)
  IRIIS                    2015/2016 to 2016/2017   578    48 (8.3)       6 (12.0)    8 (16.0)    10 (20.0)   9 (18.0)    17 (34.0)
  Total                    2014/2015 to 2019/2020   1389   105 \* (7.5)   18 (17.1)   28 (26.6)   21 (20.0)   20 (20.0)   20 (18.1)

\* Among the HCoV-positive patients, two were co-infected by two HCoVs (number of HCoVs detected = 107).

viruses-12-00630-t002_Table 2

###### 

Chronological distribution of the different viruses detected during the influenza surveillance seasons.

              Overall   Flu A   Flu B   HCoVs   HRV    RSV   Other Viruses                               
  ----------- --------- ------- ------- ------- ------ ----- --------------- ---- ----- ---- ------ ---- ------
  2014/2015   151       60      39.7    17      11.3   11    7.3             4    2.6   3    2.0    3    2.0
  2015/2016   133       25      18.8    33      24.8   6     4.5             10   7.5   3    2.3    2    1.5
  2016/2017   140       69      49.3    0       0.0    14    10.0            6    4.3   7    5.0    3    2.1
  2017/2018   150       30      20.0    35      23.3   8     5.3             9    6.0   17   11.3   17   11.3
  2018/2019   118       53      44.9    0       0.0    7     5.9             7    5.9   4    3.4    9    7.6
  2019/2020   119       26      21.8    20      16.8   11    9.2             6    5.0   3    2.5    9    7.6
  TOTAL       811       263     32.4    105     12.9   57    7.0             42   5.2   37   4.6    43   5.3

Flu A: Influenza virus A; Flu B: Influenza virus B; HCoVs: Human coronaviruses; HRV: Human rhinovirus; RSV: Respiratory syncytial virus.

viruses-12-00630-t003_Table 3

###### 

Co-pathogen detection in human coronavirus-positive patients.

  Co-Pathogen                          HCoVs   229E   OC43   NL63   HKU1   HCoV Without Species Determination
  ------------------------------------ ------- ------ ------ ------ ------ ------------------------------------
  Flu A                                9       5      1      /      2      1
  Flu B                                8       /      1      2      3      2
  RSV                                  3       /      /      1      2      /
  HRV                                  1       1      /      /      /      /
  HMPV                                 1       /      /      /      1      /
  HAdV                                 1       /      /      1      /      /
  HCoV-229E                                           /      1      /      /
  HCoV-OC43                                    /             /      1      /
  HCoV-NL63                                    1      /             /      /
  HCoV-HKU1                                    /      1      /             /
  HCoV without species determination           /      /      /      /      
  Total                                23 \*   7      3      5      9      3

\* Two co-infections with three viruses (A(H1N1)pdm09/HKU/HMPV and BYAM/NL63/HAdV) and two co-infections with two HCoVs (HCoV-229E/NL63 and HCoV-HKU1/OC43). Flu A: Influenza virus A; Flu B: Influenza virus B; HCoVs: Human coronaviruses; HRV: Human rhinovirus; RSV: Respiratory syncytial virus; HMPV: Human metapneumovirus; HAdV: Human adenovirus.

viruses-12-00630-t004_Table 4

###### 

Age, sex and clinical characteristics of ARI/ILI patients and their positivity for human coronaviruses and influenza viruses.

  ----------------------------------- --------------------------- ----------------------------------- ----------------------------- ------------------------------------- -------------------- ----------------- ------------------ --------------- --------------- --------- ------- --------------- -------------- ---------------------------- ------------ ------- -------------------- ------------ ------- --------------- ----------- --------- ------- -------- -------------- ------------
  **Collected Variable**              **All Patients ARI./ILI**   **Patients positive**               **Patients HCoVs Positive**   **Negative for All Viruses Tested**                                                                                                                                                                                                                                                                                                                
  **Influenza Virus A**               **Influenza Virus B**       **All HCoVs Positive Patients\***   ***p*-Value**                 **Single HCoV**                       **Co-Pathogen**      ***p*-Value**                        ***p*-Value**                                                                                                                                                                                                                                      
  ***n***                             **%**                       ***n***                             **%**                         ***n***                               **%**                ***n***           **%**              **FluA/HCoV**   **FluB/HCoV**   ***n***   **%**   ***n***         **%**          **singleHCoV/ Copathogen**   ***n***      **%**   **HCoV/ Negative**                                                                                              
  Number of HCoVs positive patients   1389                        100.0                               328                           23.6                                  212                  15.3              105                7.6             82              78.1      23      21.9            561            40.4                                                                                                                                                              
  Age                                 Median Age (years)          34                                  36                            28.5                                  34                   /                 /                  39.5            11.0            /         36.0    /                                                                                                                                                                                                
  Mean Age (Min-Max) (years)          34.96 (0.08--97.0)          34.53 (0.08--89)                    31.02 (0.67--91)              34.61 (0.08--90)                      37.43 (0.50--90.0)   24.5 (0.08--80)   36.73 (0.25--90)                                                                                                                                                                                                                                                      
  Age IQR (years)                     13--53                      13--51                              10--48                        11--52                                16.0--53.5           3.5--44.0         17.0--54.0                                                                                                                                                                                                                                                            
                                      ***n***                     **%**                                                             ***n***                               **%**                                  ***n***            **%**                           ***n***   **%**   ***p*-Value**                                               **n**        **%**   ***p*-Value**        ***n***      **%**   ***p*-Value**               ***n***   **%**                           
  0--14 years                         378                         27.2                                88                            26.8                                  73                   34.4              30                 28.6            **0.00005**     0.908     0.535   18              22.0           **0.00137**                  12           52.2    **0.00005**          **0.008**    124     22.1            0.406                                                 
  15--29 years                        210                         15.1                                42                            12.8                                  37                   17.5              14                 13.3            13              15.9      1       4.3             0.295          93                           16.6                                                                                                                                 
  30--44 years                        303                         21.8                                84                            25.6                                  42                   19.8              21                 20.0            17              20.7      4       17.4            1              135                          24.1                                                                                                                                 
  45--59 years                        268                         19.3                                69                            21.0                                  34                   16.0              25                 23.8            22              26.8      3       13.0            0.267          104                          18.5                                                                                                                                 
  60--74 years                        149                         10.7                                32                            9.8                                   16                   7.5               10                 9.5             8               9.8       2       8.7             1              73                           13.0                                                                                                                                 
  ≥ 75                                81                          5.8                                 13                            4.0                                   10                   4.7               5                  4.8             4               4.9       1       4.3             1              32                           5.7                                                                                                                                  
  Sex                                 Female                      758                                 54.6                          184                                   56.1                 110               51.9               51              48.6            0.782     0.216   0.633           44             53.7                         0.435        7       30.4                 **0.0174**   0.06    311             55.4        0.202                                     
  Male                                631                         45.4                                144                           43.9                                  102                  48.1              54                 51.4            38              46.3      16      69.6            250            44.6                                                                                                                                                              
                                      ***n***                     **%**                               **NA**                        ***n***                               **%**                **NA**            ***n***            **%**           **NA**          ***n***   **%**   **NA**                                                      ***n***      **%**   **NA**               ***n***      **%**   **NA**                      ***n***   **%**   **NA**                  
  Symptoms                            Fever                       1298                                95.2                          25                                    321                  98.5              2                  205             97.2            1         94      91.3            2              **0.00131**                  **0.0439**   72      88.9                 1            22      100.0           1           0.198     513     93.4     12             0.400
  Cough                               1087                        87.8                                151                           247                                   92.2                 60                173                88.7            17              84        89.4    11              0.397          1                            66           90.4    9                    18           85.7    2               0.688       418       82.9    57       0.128          
  Sore throat                         659                         53.2                                151                           125                                   46.6                 60                101                51.8            17              64        68.1    11              **0.000465**   **0.011**                    55           75.3    9                    9            42.9    2               **0.006**   267       53.0    57       **0.0068**     
  Dyspnea                             241                         19.5                                151                           49                                    14.9                 0                 31                 14.6            0               32        30.5    0               **0.000817**   **0.00152**                  29           35.4    0                    3            13.0    0               **0.04**    91        16.2    0        **0.000963**   
  Rhinorrhea                          932                         75.3                                151                           206                                   76.9                 60                150                76.9            17              83        88.3    11              **0.017**      **0.0257**                   64           87.7    9                    19           90.5    2               1           355       70.4    57       **0.000201**   
  Myalgia                             666                         69.0                                424                           123                                   70.7                 154               120                74.1            50              52        70.3    31              1              0.533                        41           71.9    25                   11           64.7    6               0.561       288       71.5    158      0.889          
  Headache                            863                         69.7                                151                           194                                   72.4                 60                147                75.4            17              73        77.7    11              0.343          0.769                        59           80.8    9                    14           66.7    2               0.233       346       68.7    57       0.0866         
  Malaise                             85                          12.0                                681                           26                                    12.7                 124               13                 14.3            121             3         3.2     11              **0.0104**     **0.00844**                  2            2.7     9                    1            4.8     2               0.536       36        14.9    319      0.002          
  Conjunctivitis                      345                         24.8                                0                             67                                    20.4                 0                 59                 27.8            0               32        30.5    0               **0.0446**     0.692                        24           29.3    0                    8            34.8    0               0.616       141       25.1    0        0.275          
  Vomiting                            151                         10.9                                0                             32                                    9.8                  0                 20                 9.4             0               15        14.3    0               0.208          0.252                        12           14.6    0                    3            13.0    0               1           66        11.8    0        0.514          
  Diarrhea                            154                         11.1                                0                             23                                    7.0                  0                 23                 10.8            0               10        9.5     0               0.401          0.845                        9            11.0    0                    1            4.3     0               0.442       68        12.1    0        0.512          
  Other symptoms                      184                         21.0                                512                           44                                    16.2                 56                21                 18.3            97              18        26.9    38              0.0521         0.192                        15           30.6    33                   3            16.7    5               0.757       82        25.0    233      0.759          
  Anormal lung auscultation           88                          26.3                                1055                          24                                    25.3                 233               8                  17.0            165             8         38.1    84              0.282          0.0709                       6            46.2    69                   2            25.0    15              0.4         34        27.2    436      0.309          
  Other variables                     Risk factors                321                                 23.5                          22                                    59                   18.3              6                  41              19.4            1         16      15.2            0              0.555                        0.4          13      15.9                 0            3       13.0            0           1         145     26.4     11             **0.0182**
  Oseltamivir                         241                         18.0                                49                            88                                    27.7                 10                29                 14.0            5               14        13.6    2               **0.00348**    1                            12           15.0    2                    2            8.7     0               0.73        88        16.4    26       0.558          
  Antibiotics                         173                         13.3                                86                            43                                    14.2                 25                18                 8.8             7               10        9.9     4               0.31           0.833                        7            8.9     3                    3            13.6    1               0.45        73        14.1    43       0.338          
  Hospitalization                     39                          2.9                                 32                            12                                    3.8                  10                7                  3.4             5               2         1.9     0               0.532          0.7                          2            2.4     0                    0            0.0     0               1           15        2.7     10       1              
  ----------------------------------- --------------------------- ----------------------------------- ----------------------------- ------------------------------------- -------------------- ----------------- ------------------ --------------- --------------- --------- ------- --------------- -------------- ---------------------------- ------------ ------- -------------------- ------------ ------- --------------- ----------- --------- ------- -------- -------------- ------------

\* Overall HCoV infections also include strains without species determination (*N* = 20).

viruses-12-00630-t005_Table 5

###### 

Description of HCoV-positive patients according to the viral strains detected.

  ----------------------------------- --------------------------------- ------------------ ------------------ ----------------------------------------- ------- --------------- --------- ------- --------------- --------- ------- --------------- ------------ -------------
  **Collected Variable**              **Distribution of HCoV Strain**                                                                                                                                                                                            
  **229E**                            **OC43**                          **NL63**           **HKU1**           ***p*-Value Variation between Species**                                                                                                            
  ***n***                             **%**                             ***n***            **%**              ***n***                                   **%**   ***n***         **%**                                                                            
  Number of HCoVs positive patients   18                                17.1               28                 26.7                                      21      20.0            20        19.0                                                                   
  Age                                 Median Age (years)                27                 31                 40                                        34.5    /                                                                                                
  Mean Age (Min-Max) (years)          31.1 (4--69)                      33.1 (0.5--90.0)   33.72 (0.08--68)   36.99 (0.83--80)                                                                                                                                   
  Age IQR (years)                     11.25--47.5                       7--48.25           15--52             4--60.25                                                                                                                                           
                                      ***n***                           **%**              ***p*-Value**      ***n***                                   **%**   ***p*-Value**   ***n***   **%**   ***p*-Value**   ***n***   **%**   ***p*-Value**                
  0--14 years                         6                                 33.3               0.156              9                                         32.1    0.0721          5         23.8    0.0721          6         30.0    0.224           0.927        
  15--29 years                        4                                 22.2               4                  14.3                                      4       19.0            1         5.0     0.46                                                           
  30--44 years                        3                                 16.7               4                  14.3                                      5       23.8            5         25.0    0.75                                                           
  45--59 years                        3                                 16.7               7                  25.0                                      6       28.6            2         10.0    0.44                                                           
  60--74 years                        2                                 11.1               2                  7.1                                       1       4.8             4         20.0    0.38                                                           
  ≥ 75                                0                                 0.0                2                  7.1                                       0       0.0             2         10.0    0.3                                                            
  Sex                                 Female                            2                  11.1               0.0000005                                 15      53.6            0.79      13      61.9            0.217     11      55.0            0.752        **0.00209**
  Male                                16                                88.9               13                 46.4                                      8       38.1            9         45.0                                                                   
                                      ***n***                           **%**              **NA**             ***n***                                   **%**   **NA**          ***n***   **%**   **NA**          ***n***   **%**   **NA**                       
  Symptoms                            Fever                             17                 94.4               0                                         26      92.9            0         16      84.2            2         19      95.0            0            0.140
  Cough                               14                                100.0              4                  22                                        91.7    4               17        89.5    2               15        78.9    1               0.261        
  Sore throat                         11                                78.6               4                  14                                        58.3    4               15        78.9    2               11        57.9    1               0.307        
  Dyspnea                             3                                 16.7               0                  4                                         14.3    0               7         33.3    0               8         40.0    0               0.138        
  Rhinorrhea                          13                                92.9               4                  23                                        95.8    4               16        84.2    2               16        84.2    1               0.509        
  Myalgia                             7                                 77.8               9                  10                                        66.7    13              13        76.5    4               12        66.7    2               0.861        
  Headache                            13                                92.9               4                  20                                        83.3    4               14        73.7    2               13        68.4    1               0.322        
  Malaise                             0                                 0.0                4                  0                                         0.0     4               0         0.0     2               3         15.8    1               **0.0247**   
  Conjunctivitis                      4                                 22.2               0                  11                                        39.3    0               6         28.6    0               6         30.0    0               0.656        
  Vomiting                            1                                 5.6                0                  5                                         17.9    0               4         19.0    0               2         10.0    0               0.543        
  Diarrhea                            1                                 5.6                0                  1                                         3.6     0               2         9.5     0               3         15.0    0               0.517        
  Other symptoms                      4                                 30.8               5                  3                                         15.0    8               2         15.4    8               3         25.0    8               0.669        
  Anormal lung auscultation           1                                 33.3               15                 4                                         66.7    22              1         16.7    15              2         33.3    14              0.343        
  Other variables                     Risk factors                      0                  0.0                0                                         3       10.7            0         3       14.3            0         5       25.0            0            0.138
  Oseltamivir                         3                                 16.7               0                  2                                         7.1     0               3         15.8    2               4         20.0    0               0.607        
  Antibiotics                         2                                 11.1               0                  1                                         3.6     0               3         15.0    1               1         5.9     3               0.515        
  Hospitalization                     1                                 5.6                0                  0                                         0.0     0               0         0.0     0               0         0.0     0               0.275        
  ----------------------------------- --------------------------------- ------------------ ------------------ ----------------------------------------- ------- --------------- --------- ------- --------------- --------- ------- --------------- ------------ -------------
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